7,788,150 Shares in Compass Therapeutics, Inc. (NASDAQ:CMPX) Acquired by Enavate Sciences GP LLC

Enavate Sciences GP LLC purchased a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,788,150 shares of the company's stock, valued at approximately $11,293,000. Compass Therapeutics makes up 8.1% of Enavate Sciences GP LLC's holdings, making the stock its 5th largest holding. Enavate Sciences GP LLC owned 5.66% of Compass Therapeutics as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after purchasing an additional 356,352 shares during the last quarter. Catalina Capital Group LLC bought a new position in shares of Compass Therapeutics during the 4th quarter valued at about $71,000. Bleakley Financial Group LLC boosted its holdings in shares of Compass Therapeutics by 250.7% during the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock valued at $58,000 after purchasing an additional 28,589 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after purchasing an additional 3,822 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on CMPX. Piper Sandler started coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their price target for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of "Buy" and a consensus target price of $13.13.

Insiders Place Their Bets

In related news, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is owned by insiders.

Compass Therapeutics Stock Performance

NASDAQ CMPX traded down $0.05 during trading on Wednesday, hitting $1.95. The stock had a trading volume of 809,182 shares, compared to its average volume of 906,774. The stock has a market capitalization of $269.65 million, a price-to-earnings ratio of -5.27 and a beta of 1.40. Compass Therapeutics, Inc. has a one year low of $0.77 and a one year high of $4.08. The stock has a 50 day simple moving average of $1.97 and a 200 day simple moving average of $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). On average, sell-side analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.